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BACKGROUND: Multi-drug Resistant Tuberculosis (MDR-TB) 
is found to be a major public health problem both in developed 
and developing countries. Ethiopia is one of the 30 high MDR-TB 
burden countries in the world. Although several studies were 
done to identify the determinants of MDR-TB, the reported 
findings are heterogeneous across the world. 
METHODS: Unmatched case-control study was conducted at 
Debre Markose Referral Hospital, Debre Birhan Referral 
Hospital, and Boru Media District Hospital in Amhara Region, 
Northern Ethiopia, from March 01/2019- April 30/2019. Cases 
were all tuberculosis patients with culture or line probe assay 
confirmed mycobacterium tuberculosis resistant to at least both 
Isoniazid and Rifampicin and registered on second-line TB 
treatment. Controls were all patients with Bacteriological 
(molecular) proven drug-susceptible TB strains and whose recent 
smears result were turned to negative and registered as cured 
from January 01/2014 – December 31/2018. A pre-tested checklist 
was used to collect the data. 
RESULT: Of the total reviewed documents (393), 98 cases and 
295 controls were involved in this study.  And, 54(55.1%) among 
cases and 162(54.9%) among controls were males. sixty 
nine(70.4%) among cases and 163(55.3) among controls were 
within the age group of 26-45 years. In the multivariable logistic 
regression analysis, age between 26-45years old (AOR=3.35; 95% 
CI: 1.15, 9.77), previous history of TB treatment (AOR= 14.2; 
95%CI: 7.8, 25.3) and being HIV positive (AOR=4.4; 95% CI: 
1.8, 10.4) were significantly associated with MDR-TB. 
CONCLUSION: Age between 26-45 years old, previously treated 
cases and TB/HIV co-infection were identified as the 
determinants of MDR-TB. Special attention should be given to 
age between 26-45 years old, previous history of TB treatment and 
TB/HIV co-infection to prevent and control MDR-TB in the local 
context. 
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Tuberculosis (TB) is an infectious disease 
caused by Mycobacterium Tuberculosis 
complex which usually infects the lung. It is one 
of the top 10 causes of death worldwide and the 
leading cause of death from a single infectious 
agent (ranking above HIV/AIDS). It was 
responsible for 1.2 million deaths among HIV-
negative and 251 000 deaths among HIV-
infected people (1). Multi-Drug Resistant TB 
(MDR-TB) is defined as mycobacterium 
Tuberculosis resistant to at least Isoniazid and 
Rifampicin (2). Drug- resistant TB continues to 
be a public health threat both in developed and 
developing countries. In 2018, there were about 
half a million new cases of Rifampicin-Resistant 
TB of which 78% had MDR-TB (2,3). MDR-TB 
is progressively increasing among new and 
previously TB treated cases. Globally, 3.5% of 
new TB cases and 18% of previously treated 
cases had MDR/RR-TB (1). Although the 
overall prevalence of TB decreased by two 
percent, the incidence of MDR-TB remain 
increasing overtime (3,4). It is more common in 
resource limited regions due to poor adherence 
to treatment and lack of infection prevention 
practices both at home and in health facilities 
(5). Although 89.7% of the cases found in 30 
high MDR-TB burden countries, it has been 
distributed in several regions in the world (2). 
According to WHO 2019 report, among all TB 
cases (10.million), 214,000 deaths were due to 
MDR-TB (1). A study conducted in South 
Africa in 2017 indicated that the mortality rate 
of MDR-TB patients was significantly high and 
more prevalent among previously TB treated 
cases (6). Ethiopia is among the 30 MDR-TB 
high burden countries with an estimated 5800 
cases and prevalence rate of 21% among 
previously treated TB patients and 2.2% among 
newly diagnosed TB patients (2,7). On average, 
Ethiopia spent 75% health-related budget and 
22.3% of annual household income on drug-
resistant TB (8,9). 
 MDR-TB mainly affects uneducated, low 
socioeconomic status and reproductive age 
group of the population (13). Although TB is 
curable, patients infected with MDR strains are 
difficult to cure, and it remains a source of 
infection for a longer period (14). Poor 
adherence to TB treatment has been also 
observed in MDR-TB patients due to drug 
toxicity, high death rates (50-80%), serious 
psychological and economic crisis for infected 
individuals and their families (15). Several risk 
factors for MDR-TB were reported from 
different studies at different times in the world 
(16). Poor drug supply, use of inappropriate 
guidelines, poor treatment adherence, poor 
infection prevention practice, improper drug 
storage, wrong dose utilization, poor supervision 
by health professionals and close contact with 
MDR-TB cases were recognized as the 
determinants of MDR-TB (15-19). 
Although some studies were conducted to 
identify the determinants of MDR-TB, the 
reported findings were heterogeneous in study 
designs and setting (15,18). Some variables like 
cigarette smoking (17, 20) and Human Immune 
Deficiency Virus (HIV) (20,22) have shown 
inconsistent relation with MDR-TB as reported 
from several studies in the past. For example, 
being HIV positive was listed as the risk factor 
for MDR-TB in some studies (21, 23, 24) while 
A systematic review and meta-analysis done on 
32 studies reported no association between 
MDR-TB and HIV infection (22). Despite the 
fact that MDR-TB continued to be an emerging 
public health threat specially in areas with 
poverty, and high prevalence of HIV, there were 
limited studies in Amhara Region with smaller 
sample size and limited study setting (22.) 
Furthermore, the study area is characterized by 
high population growth, lifestyle change of 
population and immigration of a huge number of 
people from several regions of the country. 
These encourage the demand for an up-to-date 
large scale studies in the local context. 
Therefore, the purpose of this study was to 
identify the determinant of MDR-TB among TB 
patients at selected MDR-TB treatment initiating 
centers of Amhara Region, Northern Ethiopia. 
 
 METHODS AND MATERIALS 
 
This unmatched case control study was 
conducted at three MDR-TB initiating centers 
(Debre Markose Referral Hospital, Debre Birhan 
Referral Hospital, and Boru Media District 
Hospital) in Amhara Region, North Ethiopia, 
from March 01-April 30, 2019. Amhara 
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National Regional State is the second-largest 
region which is located in the Western and 
Northern Central parts of Ethiopia; it has 12 
zones, three-city administrations, and 180 
woredas (139 rural and 41 urban). According to 
the 2017 Ethiopian Central Statistics Agency 
report, the region has a projected population of 
21.5 million people, about 80 percent of whom 
are rural farmers (23). The region has 80 
hospitals (5 referral, 2 general, and 73 primary), 
847 health centers and 3,342 health posts (23). 
Currently, a total of 14 MDR-TB treatments 
initiating centers are available, of which 3 
randomly selected MDR-TB treatment initiating 
centers; namely, Debre Markos Referral 
Hospital, Debre Birhan Referral Hospital, and 
Boru Media District Hospital were included in 
this study. the study population for cases were 
All TB patients with culture or Drug 
Susceptibility Testing (DST) confirmed TB 
strains resistant to at least Isoniazid and 
Rifampicin registered on second-line TB 
treatment in the selected MDR-TB treatment 
initiating centers from January 01/2014 – 
December 31/2018. All TB patients with 
bacteriologically proven drug- susceptible TB 
strains,whose recent smears result were turned to 
negative at 6th month and either 2nd or 5th 
months registered as cured from January 
01/2014 up to December 31/2018  were the 
study population for controls. 
          For cases All confirmed MDR-TB 
patients, whose ages ≥18 years and registered on 
second- line anti-TB treatment from January 
01/2014 upto December 31/2018 were included 
in the study. for controls All smear-positive TB 
patients, whose ages ≥18 years and complete 
their treatment in the same institution with cases 
and registered as cured from January 01/2014 to 
December 31/2018 were included. 
           Double population proportion formula 
was used to determine the sample size using 
Epi-Info version 7. HIV seropositivity was taken 
as the main research hypothesis variable and the 
sample was determined by considering the 
following assumptions: The critical value of 
95% CI (Z= 1.96), power (Z1-β) = 80%, the 
ratio of case to control 1:3, percent of exposure 
among cases (P1 = 50%) and percent of 
exposure among controls (P2= 28.9%) (24). 
Based on the above assumptions, the largest 
calculated sample size for variable HIV 
seropositive was 244. Considering the 1.5 design 
effect and 10% non-response rate, the final 
sample size became 400 (100 cases and 300 
controls). 
             The study participants were selected 
using multi-stage sampling technique at three 
randomly selected MDR-TB treatment initiating 
hospitals in the Amhara Region, Northern 
Ethiopia. The number of controls and cases from 
each MDR-TB treatment initiating center was 
allocated proportionally. After reviewing five 
years of TB patients' documents, a total of 208 
cases and 321 controls fulfilled the inclusion 
criteria. After stratification of the population 
based on their disease's status, three controls 
were selected for each case. Generally, 100 
cases and 300 controls were selected through 
simple random sampling technique using 
computer-generated random numbers. The 
outcome variable of this study was the 
presence/absence of Multi-Drug Resistant TB. 
The explanatory variables were age, sex, place 
of residence, previous history of TB treatment, 
degree of smear positivity, undernutrition, HIV 
status, Diabetes mellitus (DM) conditions and 
cigarette smoking status of the study 
participants. 
Data were collected by two trained nurses 
from TB registration book and patient charts at a 
separate room of TB wards. The data extraction 
instrument was pretested on 5% of the total 
sample size. Data collections using the 
checklists were taken place at Debre Markose 
Referral Hospital before the actual data 
collection to check the validity and consistency 
of the checklist. Then, the checklist was 
modified based on the availabilities of registered 
data both at the TB registration book and 
patients' charts. The data collector was 
monitored by one supervisor and principal 
investigator during the data collection process. 
The data were coded, entered and cleaned 
using Epi-Info version 7 and exported to 
Statistical Package for Social Science (SPSS) 
version 23. Data completeness and consistency 
were checked by running frequencies of each 
variable. In univariate analysis, cross-tabulation 
was also performed to see the distribution of 
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each independent variable with the outcome 
variable. Simple binary logistic regression 
analysis was used to select candidate variables 
for multivariable logistic regression analysis. 
Variables with p-values of less than 0.25 were 
entered into the multivariable logistic regression 
analysis model to control the effect of different 
confounding factors while assessing the effect of 
each independent variable with the outcome 
variable. Adjusted Odd Ratio (AOR) along with 
95% CI was used to determine the strength of 
association with the level of statistical 
significance p-value <0.05. The model goodness 
of fit was checked by Hosmer and Lemeshow 
test (P-value = 0.624). It was used with a 
stepwise backward likelihood ratio for 
multivariable logistic regression analysis. 
Ethical clearance was obtained from the school 
of Nursing Ethical Review Committee on behalf 
of the University of Gondar. A detailed 
explanation of the purpose, benefit, and risk of 
the research were given to the selected health 
facilities. Then, verbal consent was obtained 
from each MDR-TB treatment initiating center 
managers. Patient identification data were 





A descriptive study of the risk factors of 
MDR-TB: Among the total calculated sample 
size, 393 (98.3%) (98 cases and 295 controls) 
were included in this study. The rest seven 
reviewed document were excluded from the 
study due to incomplete data. 
The mean (+/-standard deviation [SD]) age 
of the total study antiparticles was 32.0 (+/- 
10.9) years, and males were found to be 
predominant, 216 (55%). The numbers of males 
among controls, 162(54.9%), and cases, 
54(55.1%), were nearly equal. Twenty-three 
(23.5%), 69(70.4%) and 6(6.1%) of the cases 
were found in the age group of between18-25, 
26-45 and ≥46 years old respectively. The 
majority of cases 69(70.4%) were residing in 
rural than urban area 29 (29.6%). Similarly, in 
controls, more than half of the study 
participants, 164(55.6%), were living in rural 
than urban areas. 
As shown in Table1, 42(43.9%) cases and 
120(40.7%) controls were found to be ≥+3 
bacterial loads on their sputum per field. 
Furthermore, 75(76.5%) of the cases and 
56(19%) of the controls had the previous history 
of TB treatment, and 22(22.4%) of the cases and 
7(5.8%) of the controls were co-infected with 
HIV. According to BMI classification, 9(9.2%) 
cases and 20(6.8%) controls were under 
nutrished (BMI≤18.49). A total of nine (9.2%) 
cases and twenty (6.8%) controls were 
contracted with DM. 
 
Bivariable and Multivariable analysis of the 
determinants of MDR-TB: The result from the 
multivariable analysis showed that age 26-45 
years old, previous history of TB treatment and 
HIV infection were significantly associated with 
MDR-TB in the cases as compared to the 
controls (Table 2). 
People whose ages were between 26-45 
years old were three times more likely to 
develop MDR-TB (AOR=3.3; 95% CI: 1.15, 
9.77) compared to people whose ages were 
above 46 years. Those people who had a 
previous history of TB treatment were also 
fourteen times more likely to develop MDR-TB 
than those who have not been treated before 
(AOR=14.16; 95%CI:7.80,25.38). MDR-TB 
was significantly associated with HIV infection. 
People who were co-infected with HIV were 4.4 
times more likely to develop MDR-TB than 
those TB patients who were HIV negatives 
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Table 1: Socio-demographic and medical characteristics of the study participants at selected 
MDR-TB initiating centers of Amhara region, Northern Ethiopia, January 01/2014 – 
December 31/2018, (N= 393) 
 
Variables MDR - TB cases, (N=98); N (%) Non MDR - TB (controls) 
(N=295); N (%) 
Sex   
Male 5 4 (5 5. 1 %) 1 6 2 (5 4 .9 %) 
Female 44 (4 4. 9 %) 1 3 3 (4 5 .1 %) 
Age in years   
 18 - 25 23(23.5%) 89 (30.1 %) 
 26 - 45 69 (70.4%) 163(55.3%) 
 >4 6 6(6.1%) 43(14.6%) 
Place of   Residence   
 Urban 29 (29. 6 %) 1 31 (4 4 .4 %) 
 Rural 69 (70 . 4 %) 164 (5 5 .6 %) 
Degree of smear positivity   
 +2 5 6 (5 7. 1 %) 175 (59 .3 %) 
 +3 4 2 (4 3. 9 %) 1 20 (4 0 .7 %) 
Previous treatment history   
   Yes 75 (76. 5 %)            5 6 (19 %) 
   No 23 (23. 5 %)           2 39 (8 1 %) 
HIV status   
 Positive 2 2 (2 2. 4 %)          17 (5 .8 %) 
 Negative 7 6 (7 7. 6 %)          2 7 8 (9 4 .2 %) 
B MI In kg/m 2   
 ≤18.49 9(9 .2 %)         3 2 (10. 8 %) 
 ≥18.5 89 (9 0. 8 %)        2 63 (89. 2 %) 
Contracted with DM   
 Yes 9 (9.3%)        2 0 ( 6 .8 %) 
 No 89 (90. 8 %)        2 75 (9 3 .2 %) 
smoking History   
 Yes 10(10. 2 %)       18 (6 .1 %) 
 No 88 (89. 8 %)       277 (9 3 .9 %) 
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Table 2: Bivariable and multivariable analysis of the determinants of MDR-TB at selected 
MDR- TB treatment initiating centers, Amhara Region, Northern Ethiopia (N=393) 
 
-N = number of the study subjects, COR = crude odd ratio, AOR = Adjusted odd ratio 






















COR(95%CI) AOR(95%CI) P-value 
Sex      
Male 54 162 1.01 (0.64, 1.59) 1.14(0.78,2.52) 0.25 
Female 44 133 1 1  
Age in years      
18-25 23 89 1.85(0.70,4.88) 2.39(0.76,7.58) 0.14 
26-45 69 163 3.03(1.23,7.46) 3.35(1.15,9.78) 0.03* 
≥46 6 43 1 1  
Place of 
residence 
     
Urban 29 131 0.21(0.32, 0.86) 0.62(0.34,1.12) 0.12 
Rural 69 164 1 1  
Degree of      
smear positive      
≤+2 56 175 1 1  
≥+3 42 120 0.91(0.69, 1.74) 1.51(0.84,2.71) 0.17 
Previous TB      
treatment      
Yes 75 56 13.9(8.03,24.13) 14.16(7.8,25.4) 0.001* 
No 23 239 1 1  
HIV status      
Positive 22 17 4.73 (2.39,9.36) 4.39(1.85,10.4) 0.001* 
Negative 76 278 1 1  
Body mass index      
≤18.49 9 32 0.83(0.38, 1.80) 0.83(0.30, 2.26      0.52 
≥18.5 89 263 1 1 1.000 
  Diabtes Millitues      
Yes 9 20 1.39 (0.61,3.16) 1.33(0.48,3.74) 0.58 
No 89 275     1 1  
Smoking history      
 Yes 10 18 1.75(0.78, 3.93) 2.29(0.79,6.69) 0.13 
No 88 277        1 1  
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The determinants of MDR-TB can vary 
according to the type of study design and the 
countries where the studies were conducted 
(12,15). Besides that, although Ethiopia is one of 
the 30 MDR-TB high burden countries, there 
were limited studies with soundable study 
design and larger samples to identify the risk 
factors of this disease in the local context (22). 
In the current study, age between 26-45 years 
old,  previous history of TB treatment and co-
infection with HIV were identified as the risk 
factors for MDR-TB. The study revealed that 
those people whose ages were between 26-45 
years old were 3.4 times more likely to develop 
MDR-TB compared to age older than 45 years 
(AOR=3.35; 95% CI: 1.15, 9.77). This finding is 
in line with a study done in Eastern Ethiopia 
(AOR =2.74) (25).The positive association of 
this age group with MDR-TB could be due to 
the fact that this age group has a higher tendency 
not to adhere to anti-TB medication because of 
tightness with work, travel of long distance to 
search work and addiction to alcohol compared 
to older people whose lifestyle is sedentary. 
In contrast to this finding, a single study in 
Ethiopia showed that people whose ages were 
between 18-44 years old had no difference in 
developing MDR-TB between cases and 
controls (26). This discrepancy might be related 
to the difference in study design and age 
classification. 
On the other hand, findings from Spain (27) 
and China (28) revealed that those people whose 
ages were older than 45 years old appears to be 
the predisposing factor for MDR-TB compared 
to age between 26-45 years old. This is 
explained by a difference in population 
distribution and the health policy of the country. 
The finding in this study showed that those 
TB patients who had previous history TB 
treatment were fourteen times at higher risk of 
developing MDR-TB than those who had never 
been treated for TB in their life (AOR= 14.16; 
95%CI: 7.80,25.38). This finding is comparable 
with data reported from Addis Ababa, Ethiopia 
(21,25) and Jimma in Ethiopia (24). The 
possible reason could be poor treatment 
adherence and drug storage as also evidenced for 
the possible cause of emerging MDR-TB (13). 
This finding is also in line with studies 
conducted from Namibia (29), Bangladesh (30), 
Georgia (31), China (32) and Malaysia (33). The 
possible justification could be repeated and 
inappropriate way of taking anti-TB medication 
that mutates the structure of the bacterial gene 
and develops resistance against the drugs 
(16,24). 
In this study, we also found that being HIV 
positive increases the risk of developing MDR-
TB by 4.4 times compared to HIV negative TB 
patients. The finding is consistent with studies 
conducted in Eastern Ethiopia (AOR= 2.32) 
(34)nd A addis Ababa, Ethiopia (AOR=3.1) 
(25). The possible reason could be that those TB 
patients co-infected with HIV might have high 
risk of exposure to MDR-TB cases during 
hospitalization and frequent health institution 
visiting (35). There is also high burden of TB in 
HIV positive than in HIV negative in our 
settings (5).This finding is also consistent with a 
study done in Netherland (36). The association 
between co-infection with HIV and MDR-TB 
could be due to alteration of the immune system 
that leads to an increase in the chance of 
developing MDR-TB and anti-TB drugs mal-
absorption (35). 
Contrary to the current finding, some studies 
revealed that being HIV positive was not 
significantly associated with the occurrence of 
MDR-TB (17,20,31). The discrepancy of this 
finding could be inadequate testing of MDR-TB 
(14). There is also an alternative possible 
justification for this discrepancy that might be a 
difference in the study design and socio-
economical characteristics of the countries. 
Likewise, co-nfection with HIV infection had no 
association with the occurrence of MDR-TB 
according to a systematic and meta-analysis 
study done on 32 studies in South Africa (19). 
The possible justification might be that the 
Meta-analysis was done among studies with a 
cross-sectional study design which is a poor 
design for studying associations (cause-effect 
relationship), unlike a case-control study which 
we have used in our study and relatively good 
for studying determinants than cross-sectional 
study. 
Generally, in this study, age between 26-45 
years old, previous history of TB treatment and 
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co-infection with HIV were identified as the 
determinants for MDR-TB. Therefore, special 
attention should be given for younger age groups 
of the population, previous history of TB 
treatment and co-infected with HIV to prevent 
and control national MDR-TB burden according 
to the local context to keep the community 
healthy and to avert the rising problem in 
Amhara Region as well as the country. 
Inability to include some important 
variables in this study (like frequency of 
hospitalization, treatment adherence, and alcohol 
consumption) because of the incompleteness of 
data about these variables on registration book 
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